Abstract 5771
Background
Hyponatremia, usually defined as the sodium serum level < 135 mEq/l (mmol/l), is a common electrolyte disorder in the clinical practice.1 Despite its often benign course, it can rapidly evolve into a life threatening condition mainly due to neurological symptoms. Moreover, in cancer patients, hyponatremia is significantly associated with reduced overall survival.2 In cancer patients hyponatremia can occur due to malignancy as well as chemotherapy.3 Many chemotherapy drugs have been reported to induce hyponatremia.4 This study aims to determine which chemotherapeutic drugs used in hematological patients are mostly associated with hyponatremia.
Methods
This study analyzed retrospectively the data from 189 patients with diagnosed haematological malignancies that developed hyponatremia while undergoing chemotherapy. The period of observation was determined to start at the first day of a chemotherapy cycle until the 3rd day after the end of a cycle. For the purpose of this study, hyponatremia was defined as serum sodium level < 135 mEq/l (mmol/l).
Results
In our cohort of 189 patients with hyponatremia the most predominant hematological malignancy was Multiple Myeloma, which was present in 56 (29.6%) of the included patients and was followed by diffuse large B-cell Lymphoma with 34 (13.2%) patients. The median age of the studied cohort was 68 years (range 33-84 years).The mean value of serum sodium was 130.4 ± 0.27 mEq/l. 42 (22.4 %) patients had hyponatremia in the 4th cycle of the chemotherapy, with 101 (53.4%) patients developing hyponatremia in the first 4 cycles of the chemotherapy. From all patients with hyponatremia (n = 189), 43 (22.7%) received Cyclophosphamide, 38 (20.1%) Vincristine, 85 (44.9%) Cyclophosphamide and Vincristine as part of a combination, 20 (10.5%) Methothrexate, 18 (9.5%) Cisplatin and 8 (4.2%) Daratumumab.
Conclusions
Patient with hematological malignancies are at increased risk of hyponatremia possibly induced by chemotherapy. The combination regimens seem to increase the risk of developing hyponatremia substantially. In which way the occurrence of hyponatremia depends on cofactors such as infusion schemas or tumor lysis has to be evaluated in prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757 - Development of chimeric antigenic receptor (CAR) against VEGFR2 for solid tumor treatment
Presenter: Li-Shuang Ai
Session: Poster Display session 1
Resources:
Abstract
4156 - Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells.
Presenter: Nunzia Matrone
Session: Poster Display session 1
Resources:
Abstract
2949 - EGFR-mediated PD-L1 upregulation in HER2+ breast cancer (BC) cell line models
Presenter: Nicola Gaynor
Session: Poster Display session 1
Resources:
Abstract
4270 - The impact of cortisol on immune cells and its effect on cancer-immune cells co-culture in a 3D spheroid of ovarian cancer
Presenter: Maysa Al-natsheh
Session: Poster Display session 1
Resources:
Abstract
1568 - Application of sonoporation to increase anticancer drug efficacy in 2D and 3D NSCLC cell cultures
Presenter: Vilma Petrikaite
Session: Poster Display session 1
Resources:
Abstract
5400 - Tr1-like cells in human peripheral blood are part of the T effector memory pool and are preferentially stimulated via CD55
Presenter: Iniobong Charles
Session: Poster Display session 1
Resources:
Abstract
5817 - Functional analysis of tumor infiltrating lymphocytes in triple negative breast cancer focusing on granzyme B
Presenter: Hitomi Kawaji
Session: Poster Display session 1
Resources:
Abstract
2287 - Aberrant glycolysis associates with inflammatory tumor microenvironment and promotes metastasis in triple-negative breast cancer
Presenter: Chengwei Lin
Session: Poster Display session 1
Resources:
Abstract
735 - Anti-cancer effects of differentiation-inducing factor-1 in triple negative breast cancer.
Presenter: Fumi Tetsuo
Session: Poster Display session 1
Resources:
Abstract
2105 - The Inhibitory Effect in Oral Squamous Cell Carcinoma Cells by Knocking down Matrix Metalloproteinase 9
Presenter: Xinyan Zhang
Session: Poster Display session 1
Resources:
Abstract